Varenicline, naltrexone, and their combination for heavy-drinking smokers: Preliminary neuroimaging findings

American Journal of Drug and Alcohol Abuse

Volumn 41, Issue 1, 2015, Pages 35-44

  Ray, Lara A ^a   Courtney, Kelly E ^a   Ghahremani, Dara G ^a   Miotto, Karen ^a   Brody, Arthur ^a   London, Edythe D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Craving; FMRI; Heavy drinker; Naltrexone; Smoker; Varenicline

Indexed keywords

NALTREXONE; PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NARCOTIC ANTAGONIST; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ADULT; ANTERIOR CINGULATE; ARTICLE; ASSOCIATION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL NEUROIMAGING; HUMAN; MALE; NEUROIMAGING; NUCLEUS ACCUMBENS; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STEADY STATE; TITRIMETRY; ALCOHOLISM; BRAIN; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ALCOHOLISM; BENZAZEPINES; BRAIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; VARENICLINE;

EID: 84917711078     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2014.927881     Document Type: Article

References (64)

1. Dawson DA. Drinking as a risk factor for sustained smoking. Drug Alcohol Depend 2000;59:235-249.
2. Toll BA, Cummings KM, O'Malley SS, Carlin-Menter S, McKee SA, Hyland A, Wu R, et al. Tobacco quitlines need to assess and intervene with callers' hazardous drinking. Alcohol Clin Exp Res 2012;36:1653-1658.
3. Durazzo TC, Cardenas VA, Studholme C, Weiner MW, Meyerhoff DJ. Non-Treatment-seeking heavy drinkers: Effects of chronic cigarette smoking on brain structure. Drug Alcohol Depend 2007; 87:76-82.
4. Ebbert JO, Janney CA, Sellers TA, Folsom AR, Cerhan JR. The association of alcohol consumption with coronary heart disease mortality and cancer incidence varies by smoking history. J Gen Intern Med 2005;20:14-20.
5. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control 1997;6:S57-S62.
6. Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. Nicotine Tob Res 2010;12:781-785.
7. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci 2005;8:1465-1470.
8. Littleton J, Barron S, Prendergast M, Nixon SJ. Smoking kills (alcoholics)! shouldn't we do something about it? Alcohol Alcohol 2007;42:167-173.
9. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296:47-55.
10. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48: 3474-3477.
11. Glover ED, Rath JM. Varenicline: Progress in smoking cessation treatment. Expert Opin Pharmacother 2007;8:1757-1767.
12. Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs 2006;21:433-436.
13. Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother 2007;41:95-99.
14. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, Karver SB, Small BJ. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl) 2012;218:391-403.
15. Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-Treatment seeking smokers. J Psychopharmacol 2012;26:1383-1390.
16. Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry 2010;67:715-721.
17. Loughead J, Ray R, Wileyto EP, Ruparel K, O'Donnell GP, Senecal N, Siegel S, et al. Brain activity and emotional processing in smokers treated with varenicline. Addict Biol 2013;18:732-738.
18. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, et al. Effects of varenicline on smoking cue-Triggered neural and craving responses. Arch Gen Psychiatry 2011;68:516-526.
19. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-Analysis. Ann Med 2012;44:588-597.
20. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63.
21. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo-And bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-1568.
22. Oncken C, Gonzales D, Nides M, Rennard S,Watsky E, Billing CB, Anziano R, Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166: 1571-1577.
23. Williams KE, Reeves KR, Billing Jr. CB, Pennington AM, Gong J. A double-blind study evaluating the long-Term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801.
24. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA 2006; 295:2003-2017.
25. Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis 2008;27:65-72.
26. King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine Tob Res 2006;8: 671-682.
27. Byars JA, Frost-Pineda K, Jacobs WS, Gold MS. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis 2005;24:49-60.
28. O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 2006;166:667-674.
29. Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch smoking cessation: A preliminary study. Nicotine Tob Res 2003;5:851-857.
30. Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict Behav 2008;33: 173-179.
31. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H, Matthews AK, Stachoviak RJ. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol 2012;32:630-636.
32. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study. Alcohol Clin Exp Res 2009;33:1044-1050.
33. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 2008;65:466-475.
34. Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology 2013;38:414-422.
35. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, et al. Varenicline reduces alcohol selfadministration in heavy-drinking smokers. Biol Psychiatry 2009;66: 185-190.
36. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 2011;215:655-663.
37. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012;223:299-306.
38. Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-Analysis and systematic review. Addict Biol 2013;18:121-133.
39. Engelmann JM, Versace F, Robinson JD, Minnix JA, Lam CY, Cui Y, Brown VL, Cinciripini PM. Neural substrates of smoking cue reactivity: A meta-Analysis of fMRI studies. Neuroimage 2012; 60:252-262.
40. NIAAA. The physicians' guide to helping patietns with alcohol problems. Bethesda, MD: National Institutes of Health; 1995.
41. Beck AT, Steer RA, Brown G. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
42. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: Human laboratory findings. Psychopharmacology (Berl) 2014. [Epub ahead of print].
43. O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol 2009;12: 589-597.
44. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996;20: 1412-1417.
45. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86: 1119-1127.
46. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E. The reliability of a timeline method for assessing normal drinker college students' recent drinking history: Utility for alcohol research. Addict Behav 1986;11:149-161.
47. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, et al. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry 2002;59: 1162-1172.
48. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 2006;40:404-418.
49. McClernon FJ, Gilbert DG. Human functional neuroimaging in nicotine and tobacco research: Basics, background, and beyond. Nicotine Tob Res 2004;6:941-959.
50. McClernon FJ, Hiott FB, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology 2005;30: 1940-1947.
51. McClernon FJ, Kozink RV, Rose JE. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology 2008;33:2148-2157.
52. King A, McNamara P, Angstadt M, Phan KL. Neural substrates of alcohol-induced smoking urge in heavy drinking nondaily smokers. Neuropsychopharmacology 2010;35:692-701.
53. Andersson J, Jenkinson M, Smith S. Non-linear registration. FMRIB 2007; Technical report TR07JA2.
54. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907-922.
55. Esterman M, Tamber-Rosenau BJ, Chiu YC, Yantis S. Avoiding non-independence in fMRI data analysis: Leave one subject out. Neuroimage 2010;50:572-576.
56. Worsley KJ. Statistical analysis of activation images. In: Jezzard P, Matthews PM, Smith SM, eds. Functional MRI: An introduction to methods. New York: Oxford University Press; 2001.
57. Hughes J, Hatsukami DK. Errors in using tobacco withdrawal scale. Tob Control 1998;7:92-93.
58. Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, et al. Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry 2007;62:642-651.
59. Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, Gan JJ, Costello MR, et al. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry 2011;68:505-515.
60. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O'Malley SS. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug Alcohol Depend 2010;111:200-206.
61. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-Term smoking cessation weight gain in women but not men: A randomized controlled trial. Biol Psychiatry 2013;73:924-930.
62. McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob Res 2012;14:1362-1367.
63. Ray LA, Hutchison KE, Tartter M. Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des 2010;16:2149-2158.
64. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, et al. Medications development to treat alcohol dependence: A vision for the next decade. Addict Biol 2012;17:513-527.